Multiple endocrine neoplasia type 1 screening
|
Multiple endocrine neoplasia type 1 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Multiple endocrine neoplasia type 1 screening On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 screening |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
|
Risk calculators and risk factors for Multiple endocrine neoplasia type 1 screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the National Caner Institute, screening for multiple endocrine neoplasia type 1 by imaging studies such as brain MRI, abdominal CT and abdominal MRI is recommended every 3-5 year among patients with pituitary tumors and pancreatic neuroendocrine tumors respectively. Biochemical tests such as serum prolactin, insulin-like growth factor 1, fasting total serum calcium, ionized calcium, parathyroid hormone, fasting serum gastrin, chromogranin A, pancreatic polypeptide, glucagon and vaso-intestinal polypeptide are recommended every year among patients with pituitary tumors, pancreatic neuroendocrine tumors and primary hyperparathyroidism.
Screening
Screening and surveillance for multiple endocrine neoplasia type 1 may employ a combination of biochemical tests and imaging. Available recommendations are summarized in the following table. [1][2][3][4][5]
| Biochemical Test or Procedure | Condition Screened For | Age Screening Initiated (y) | Frequency |
|---|---|---|---|
| Serum prolactin and/or insulin-like growth factor 1 | Pituitary tumors | 5 | Every 1 year |
| Fasting total serum calcium and/or ionized calcium and parathyroid hormone | Parathyroidtumors and primary hyperparathyroidism | 8 | Every 1 year |
| Fasting serum gastrin | Duodenopancreatic gastrinoma | 20 | Every 1 year |
| Chromogranin A, pancreatic polypeptide, glucagon, and vasointestinal polypeptide | Pancreatic neuroendocrine tumors | <10years | Every 1 year |
| Fasting glucose and insulin | Insulinoma | 5 | Every 1 year |
| Brain MRI | Pituitary tumors | 5 | Every 3–5 years based on biochemical results |
| Abdominal CT or MRI | Pancreatic neuroendocrine tumors | 20 | Every 3–5 years based on biochemical results |
| Abdominal CT, MRI, or endoscopic US | Pancreatic neuroendocrine tumors | <10 | Every 1 year |
References
- ↑ Skogseid B, Eriksson B, Lundqvist G, Lörelius LE, Rastad J, Wide L; et al. (1991). "Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds". J Clin Endocrinol Metab. 73 (2): 281–7. doi:10.1210/jcem-73-2-281. PMID 1677362.
- ↑ Stock JL, Warth MR, Teh BT, Coderre JA, Overdorf JH, Baumann G; et al. (1997). "A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13". J Clin Endocrinol Metab. 82 (2): 486–92. doi:10.1210/jcem.82.2.3730. PMID 9024241.
- ↑ Baudin E, Bidart JM, Rougier P, Lazar V, Ruffié P, Ropers J; et al. (1999). "Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors". J Clin Endocrinol Metab. 84 (1): 69–75. doi:10.1210/jcem.84.1.5445. PMID 9920064.
- ↑ Newey PJ, Jeyabalan J, Walls GV, Christie PT, Gleeson FV, Gould S; et al. (2009). "Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors". J Clin Endocrinol Metab. 94 (10): 3640–6. doi:10.1210/jc.2009-0564. PMID 19622622.
- ↑ Falchetti A (2010). "Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how". F1000 Med Rep. 2. doi:10.3410/M2-14. PMC 2948394. PMID 20948872.